Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Elevation Oncology in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.21) EPS.
A number of other analysts have also recently weighed in on ELEV. William Blair assumed coverage on Elevation Oncology in a research note on Friday, January 3rd. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a research note on Tuesday, January 14th. Stephens reiterated an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a research report on Friday, December 6th. Finally, JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Elevation Oncology presently has a consensus rating of “Buy” and a consensus target price of $7.20.
Elevation Oncology Stock Down 5.8 %
Elevation Oncology stock opened at $0.63 on Friday. Elevation Oncology has a 1-year low of $0.50 and a 1-year high of $5.83. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77. The stock has a market cap of $37.31 million, a PE ratio of -0.77 and a beta of 1.31. The stock’s fifty day moving average is $0.65 and its two-hundred day moving average is $0.78.
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02).
Institutional Trading of Elevation Oncology
A number of hedge funds and other institutional investors have recently made changes to their positions in ELEV. Frazier Life Sciences Management L.P. grew its holdings in shares of Elevation Oncology by 102.6% during the third quarter. Frazier Life Sciences Management L.P. now owns 5,993,579 shares of the company’s stock worth $3,596,000 after buying an additional 3,035,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Elevation Oncology by 7.6% during the third quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock worth $666,000 after buying an additional 78,509 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in shares of Elevation Oncology by 227.2% during the third quarter. Sphera Funds Management LTD. now owns 1,079,762 shares of the company’s stock worth $648,000 after buying an additional 749,762 shares during the last quarter. State Street Corp grew its holdings in shares of Elevation Oncology by 13.5% during the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after buying an additional 120,993 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Elevation Oncology during the third quarter worth about $260,000. Institutional investors and hedge funds own 83.70% of the company’s stock.
Elevation Oncology Company Profile
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Featured Stories
- Five stocks we like better than Elevation Oncology
- The Role Economic Reports Play in a Successful Investment Strategy
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What is the NASDAQ Stock Exchange?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.